Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL33526217 | 0.85 | CYP3A4 (0.41) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| Hydrochloric Acid SCHEMBL33525691 | 0.85 | CYP3A4 (0.41) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| Hydrochloric Acid SCHEMBL33526406 | 0.85 | CYP3A4 (0.41) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL31291962 | 0.84 | CYP3A4 (0.48) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| Trifluoroacetic Acid SCHEMBL33525765 | 0.84 | CYP3A4 (0.38) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL14932741 | 0.84 | CYP3A4 (0.44) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL15114594 | 0.84 | CYP3A4 (0.44) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL5376558 | 0.81 | OPRM1 (0.41) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL5390425 | 0.79 | DPP4 (0.42) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL5381519 | 0.79 | OPRM1 (0.44) | CYP3A4TSHRTDP1MAPTAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | ELI LILLY AND COMPANY (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260092075-A1 | KRAS INHIBITORS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | KRAS, NRAS, HRAS | CYP3A4 1708/4885TSHR 1942/4885TDP1 3281/4885 |
| US-20260092075-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | CYP3A4 1584/4885TSHR 2220/4885TDP1 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.